Advicenne SA

1:45 PM - 2:00 PM (PDT), Wednesday, June 15, 2022
At Advicenne we are committed to developing a robust, valuable, and sustainable portfolio of products that address the unmet needs of rare renal diseases.

Our lead product ADV7103 is currently approved for the treatment of distal renal tubular acidosis (dRTA) in Europe and entering the PIII development phase in the United States. This product is also under development for Cystinuria in both Europe and the United States.
Ticker:
ADVIC
Exchange:
Euronext Paris
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
France
Year Founded:
2010
Main Therapeutic Focus:
Lead Product in Development:
Sibnayal
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
photo
US General Manager
Advicenne